JP2023532134A - 網膜変性の処置において使用するための環式化合物 - Google Patents

網膜変性の処置において使用するための環式化合物 Download PDF

Info

Publication number
JP2023532134A
JP2023532134A JP2022581456A JP2022581456A JP2023532134A JP 2023532134 A JP2023532134 A JP 2023532134A JP 2022581456 A JP2022581456 A JP 2022581456A JP 2022581456 A JP2022581456 A JP 2022581456A JP 2023532134 A JP2023532134 A JP 2023532134A
Authority
JP
Japan
Prior art keywords
compound
formula
heteroaliphatic
subject
aromatic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022581456A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023532134A5 (https=
Inventor
アナンド スワループ，
ユー ホリー チェン，
マンジュ スワループ，
ウェイ ジェン，
グレゴリー タワ，
アヌパム モンダル，
サマンサ ペイパル，
ウェンウェイ ファン，
ジジ ルオ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of JP2023532134A publication Critical patent/JP2023532134A/ja
Publication of JP2023532134A5 publication Critical patent/JP2023532134A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/473—Quinolines; Isoquinolines ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022581456A 2020-07-02 2021-07-01 網膜変性の処置において使用するための環式化合物 Pending JP2023532134A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063047858P 2020-07-02 2020-07-02
US63/047,858 2020-07-02
PCT/US2021/040157 WO2022006439A2 (en) 2020-07-02 2021-07-01 Compound embodiments for treating retinal degeneration and method embodiments of making and using the same

Publications (2)

Publication Number Publication Date
JP2023532134A true JP2023532134A (ja) 2023-07-26
JP2023532134A5 JP2023532134A5 (https=) 2024-07-04

Family

ID=77227100

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022581456A Pending JP2023532134A (ja) 2020-07-02 2021-07-01 網膜変性の処置において使用するための環式化合物

Country Status (6)

Country Link
US (1) US20230301984A1 (https=)
EP (1) EP4175636A2 (https=)
JP (1) JP2023532134A (https=)
AU (1) AU2021300425A1 (https=)
CA (1) CA3186586A1 (https=)
WO (1) WO2022006439A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4705277A1 (en) * 2023-04-27 2026-03-11 Kiora Pharmaceuticals Pty Ltd Method of treating vision loss in a human subject with photoreactive compounds

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009035534A2 (en) * 2007-09-07 2009-03-19 The Cleveland Clinic Foundation Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
JP2009533356A (ja) * 2006-04-14 2009-09-17 プラナ バイオテクノロジー リミティッド 加齢黄斑変性症（ａｍｄ）の処置方法
WO2015120115A1 (en) * 2014-02-05 2015-08-13 The Board Of Regents Of The University Of Oklahoma Compositions for treating retinal degeneration and methods of production and use thereof
WO2016044219A1 (en) * 2014-09-15 2016-03-24 Trustees Of Boston University Therapeutic and research application of pdcl3
JP2018508585A (ja) * 2015-03-16 2018-03-29 ミレカ メディシンズ ゲーエムベーハー ｃＧＭＰアナログの標的化されたリポソーム送達
WO2020080275A1 (ja) * 2018-10-15 2020-04-23 国立大学法人大阪大学 網膜および／または光受容に関連する症状の改善または予防用医薬ならびに網膜および／または光受容に関連する症状を改善または予防する物質のスクリーニング方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0489108B1 (en) * 1989-08-21 1996-03-13 Beth Israel Hospital Association Use of spiperone derivatives for immunosuppression
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
US5725493A (en) 1994-12-12 1998-03-10 Avery; Robert Logan Intravitreal medicine delivery
US6299895B1 (en) 1997-03-24 2001-10-09 Neurotech S.A. Device and method for treating ophthalmic diseases
CA2383499C (en) 1999-10-21 2009-11-24 Alcon Universal Ltd. Drug delivery device
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
WO2009089399A2 (en) * 2008-01-10 2009-07-16 Bausch & Lomb Incorporated Compositions comprising toll-like receptor or coreceptor antagonists and methods for ocular neuroprotection

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009533356A (ja) * 2006-04-14 2009-09-17 プラナ バイオテクノロジー リミティッド 加齢黄斑変性症（ａｍｄ）の処置方法
WO2009035534A2 (en) * 2007-09-07 2009-03-19 The Cleveland Clinic Foundation Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
WO2015120115A1 (en) * 2014-02-05 2015-08-13 The Board Of Regents Of The University Of Oklahoma Compositions for treating retinal degeneration and methods of production and use thereof
WO2016044219A1 (en) * 2014-09-15 2016-03-24 Trustees Of Boston University Therapeutic and research application of pdcl3
JP2018508585A (ja) * 2015-03-16 2018-03-29 ミレカ メディシンズ ゲーエムベーハー ｃＧＭＰアナログの標的化されたリポソーム送達
WO2020080275A1 (ja) * 2018-10-15 2020-04-23 国立大学法人大阪大学 網膜および／または光受容に関連する症状の改善または予防用医薬ならびに網膜および／または光受容に関連する症状を改善または予防する物質のスクリーニング方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
AUTOPHAGY, vol. 10, no. 11, JPN6025032440, 2014, pages 1989 - 2005, ISSN: 0005660118 *
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 462, JPN6025032439, 2015, pages 402 - 408, ISSN: 0005660117 *

Also Published As

Publication number Publication date
US20230301984A1 (en) 2023-09-28
AU2021300425A1 (en) 2023-02-02
WO2022006439A3 (en) 2022-02-10
EP4175636A2 (en) 2023-05-10
CA3186586A1 (en) 2022-01-06
WO2022006439A2 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
KR101851810B1 (ko) 아밀로이드 또는 아밀로이드-유사 단백질과 관련된 질환의 치료를 위한 신규 화합물
JP7757036B2 (ja) Ｋｖ７チャネル活性化剤の構成および使用方法
KR102726637B1 (ko) 6-아미노이소퀴놀린의 일가-(산) 염 및 이의 용도
JP6148270B2 (ja) ３，６−二置換キサンチリウム塩
CN110431130A (zh) 多晶型化合物和其用途
JP2024144702A (ja) 網膜疾患の治療のための眼内または経口投与用医薬組成物
JP2023532134A (ja) 網膜変性の処置において使用するための環式化合物
US8987253B2 (en) Compound having activity of blocking NMDA receptor channel, and pharmaceutical agent using the same
US6602865B1 (en) Pyridazino(4,5-b)(1,5)oxazepinone, -thiazepinone and -diazepinone compounds
CN114072146A (zh) 用于在神经恢复中使用的吲哚化合物
CN1225093A (zh) 苯并[g]喹啉衍生物
HK1176611B (en) Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
HK1176611A (en) Novel compounds for the treatment of diseases associated with amyloid or amyloid-like proteins

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240626

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240626

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250807

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260209

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260304